Liminatus Pharma, Inc. (LIMN)Healthcare | Biotechnology | Cerritos, United States | NasdaqCM
3.25 USD
-0.27
(-7.539%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 3.23 -0.02 (-0.020%) ⇩ (Oct. 14, 2026, 6 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:07 a.m. EDT
The investment case for this biotech firm is effectively extinguished by a catastrophic multi-year price collapse and imminent delisting. While the company recently announced a reverse split and a public offering to address compliance issues, the market has already punished the business severely, dropping from a peak of $141.50 to under $4.00—a loss of over 97% from the high and a complete erasure of equity value relative to the previous trading range. The price history reveals a structural implosion rather than a temporary correction, with the asset trading at a fraction of its book value and generating massive negative free cash flow. There is no dividend to provide income, and the balance sheet shows significant debt against minimal assets, creating a precarious situation where capital preservation is impossible. Any potential catalyst from the pending merger or reverse split is currently outweighed by the existential risk of delisting and the sheer magnitude of the prior decline, making this a clear avoidance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.181453 |
| MSTL | 0.275248 |
| AutoARIMA | 0.285559 |
| AutoETS | 0.288052 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 5.73 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.169 |
| Excess Kurtosis | 0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 479.854 |
| Market Cap | 4,365,423 |
| Beta | 0.75 |
| Previous Name | Liminatus Pharma, LLC |
| Website | https://liminatuspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.946281 |
| Address1 | 12,611 Hiddencreek Way |
| Address2 | Unit C |
| All Time High | 1,683.0 |
| All Time Low | 3.25 |
| Ask | 3.92 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 22,400 |
| Average Daily Volume3 Month | 444,568 |
| Average Volume | 444,568 |
| Average Volume10Days | 22,400 |
| Beta | 0.754 |
| Bid | 2.76 |
| Bid Size | 1 |
| Book Value | 0.269 |
| City | Cerritos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.25 |
| Current Ratio | 1.116 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.55 |
| Day Low | 3.25 |
| Debt To Equity | 479.854 |
| Display Name | Liminatus Pharma |
| Dividend Yield | 0.0 |
| Ebitda | -4,063,116 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.687 |
| Enterprise Value | 2,790,826 |
| Eps Trailing Twelve Months | -23.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3604 |
| Fifty Day Average Change | -1.1104002 |
| Fifty Day Average Change Percent | -0.25465557 |
| Fifty Two Week Change Percent | -94.628105 |
| Fifty Two Week High | 141.5 |
| Fifty Two Week High Change | -138.25 |
| Fifty Two Week High Change Percent | -0.9770318 |
| Fifty Two Week Low | 3.25 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 3.25 - 141.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,746,192,600,000 |
| Float Shares | 1,023,188 |
| Free Cashflow | -10,005,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Fullday Change | -0.2850001 |
| Fullday Change Percent | -8.10811 |
| Fullday Price | 3.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27185 |
| Held Percent Institutions | 0.014090001 |
| Implied Shares Outstanding | 1,343,207 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-05-01 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,787,270,400 |
| Last Split Factor | 1:50 |
| Long Business Summary | Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California. |
| Long Name | Liminatus Pharma, Inc. |
| Market | us_market |
| Market Cap | 4,365,423 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_570895157 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -12,523,251 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,413,128 |
| Open | 3.48 |
| Operating Cashflow | -3,972,747 |
| Operating Margins | 0.0 |
| Phone | 213 273 5453 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.61538404 |
| Post Market Price | 3.23 |
| Post Market Time | 1,792,015,242 |
| Prev Name | Liminatus Pharma, LLC |
| Previous Close | 3.515 |
| Price Hint | 4 |
| Price To Book | 12.081784 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.992 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.265 |
| Regular Market Change Percent | -7.53912 |
| Regular Market Day High | 3.55 |
| Regular Market Day Low | 3.25 |
| Regular Market Day Range | 3.25 - 3.55 |
| Regular Market Open | 3.48 |
| Regular Market Previous Close | 3.515 |
| Regular Market Price | 3.25 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 20,072 |
| Return On Assets | -0.95652 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,343,207 |
| Shares Percent Shares Out | 0.0332 |
| Shares Short | 44,566 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 95,505 |
| Short Name | Liminatus Pharma, Inc. |
| Short Percent Of Float | 0.041199997 |
| Short Ratio | 1.62 |
| Source Interval | 15 |
| State | CA |
| Symbol | LIMN |
| Total Cash | 3,017,096 |
| Total Cash Per Share | 2.246 |
| Total Debt | 1,442,500 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -23.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.0866 |
| Two Hundred Day Average Change | -9.8366 |
| Two Hundred Day Average Change Percent | -0.7516544 |
| Type Disp | Equity |
| Volume | 20,072 |
| Website | https://liminatuspharma.com |
| Zip | 90,703 |